ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0573 • ACR Convergence 2021

    Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111

    Hafsah Nabi1, Bente Glintborg2, Anne Gitte Loft3, Oliver Hendricks4, Jens Kristian Pedersen5, Søren Andreas Just6, Rabiah Ahmed7, Kamilla Danebod7, Heidi Munk8, Ada Colic9, Asta Linauskas10, Dorte Vendelbo Jensen11, Johnny Raun12, Jolanta Grydehøj13, Louise Brot Christensen14, Natalia Manilo15, Niels Lomborg16, Salome Kristensen17, Frank Mehnert18, Niels Steen Krogh19 and Merete Hetland20, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, 2COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 4Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Snderborg, Denmark, 5Section of Rheumatology, Department of Medicine, Svendborg Hospital – Odense University Hospital, Svendborg, Denmark, 6Section of Rheumatology, Dept. of Medicine, Svendborg Hospital, Svendborg, Denmark, 7Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen University Hospital, Glostrup, Copenhagen, Denmark, 8Department of Rheumatology, Odense University Hospital, Odense, Denmark, 9Department of Rheumatology, Zealand University Hospital, Køge, Denmark, 10Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark, 11Department of Internal Medicine, Rønne Hospital, Rønne, Denmark, 12Department of Rheumatology, Sygehus Lillebælt, Fredericia, Denmark, 13Department of Rheumatology, Holstebro Hospital, Holstebro, Denmark, 14Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark, 15Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, 16Department of Rheumatology, Vejle Hospital Lillebælt, Vejle, Odense C, Denmark, 17Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 18Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 19ZiteLab ApS, Copenhagen, Denmark, Frederiksberg, Denmark, 20DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark

    Background/Purpose: In routine care, biosimilar to biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of…
  • Abstract Number: 0604 • ACR Convergence 2021

    Disparities in Burden of Disease in Patients with RA Across Racial and Ethnic Groups

    Jacqueline O’Brien1, Sang Hee Park2, Taylor Blachley1, Maya Marchese1, Nicole Middaugh1, Xue Han2, Keith Wittstock2 and Leslie Harrold1, 1CorEvitas, LLC, Waltham, MA, 2Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Prior research has shown that differences exist in disease activity and clinical outcomes for RA across racial and ethnic groups in the US.1 This…
  • Abstract Number: 0757 • ACR Convergence 2021

    Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study

    Paul Studenic1, Aliaksandra Baranskaya2, Stanley Cohen3, Nancy Shadick4, Christine Iannaccone5, Maria Dahl Mjaavatten6, Elisabeth Lie7, Tore Kvien8, Josef Smolen9, Daniel Aletaha10 and Helga Radner9, 1Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, 2Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3Metroplex Clinical Research Center, Dallas, TX, 4Brigham & Women's Hospital, Boston, MA, 5Brigham and Women’s Hospital, Topsfield, MA, 6Diakonhjemmet Hospital, Haslum, Norway, 7Diakonhjemmet Hospital, Oslo, Nepal, 8Diakonhjemmet Hospital, Oslo, Norway, 9Medical University of Vienna, Vienna, Austria, 10Medical University Vienna, Vienna, Austria

    Background/Purpose: The patient global assessment (PGA), typically assessed as 'Considering all of the ways your arthritis has affected you, how do you feel your arthritis…
  • Abstract Number: 0799 • ACR Convergence 2021

    Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission

    Kelly O'Neill1, Kathryne Marks2, Pamela Sinicrope3, Cynthia Crowson4, Elena Myasoedova3 and John Davis3, 1Rheumatoid Patient Foundation, Lutz, FL, 2Rheumatoid Patient Foundation, Boston, MA, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic, Eyota, MN

    Background/Purpose: Remission is a well-established optimal outcome in rheumatoid arthritis (RA) treatment, yet a minority of patients reach this goal. There is not one recognized…
  • Abstract Number: 0817 • ACR Convergence 2021

    Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13

    Hubert MAROTTE1, Maryse Assing2, Nadir Mammar2, Yves Brault3 and Bruno Fautrel4, 1Rheumatology department - Unisersity Hospital of Saint-Etienne, Saint-Etienne, France, 2Inflammation & Immunology - Pfizer, Paris, France, 3Pfizer, Paris, France, 4Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France

    Background/Purpose: ReFLECT study has been carried out to investigate real life use of CT-P13, the first monoclonal antibody biosimilar to infliximab (IFX) originator.Methods: ReFLECT is…
  • Abstract Number: 0834 • ACR Convergence 2021

    Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry

    Anthony Sebba1, Clifton Bingham2, Vivian Bykerk3, Stefano Fiore4, Kerri Ford5, Jud C Janak6, Dimitrios Pappas6, Taylor Blachley6, Swapna Dave6, Joel Kremer7, Miao Yu6 and Ernest Choy8, 1Division of Rheumatology, University of South Florida, Tampa, FL, 2Johns Hopkins University, Baltimore, MD, 3Division of Rheumatology, Hospital for Special Surgery, New York City, NY, 4Sanofi, Bridgewater, NJ, 5Sanofi, Cambridge, MA, 6CorEvitas, LLC, Waltham, MA, 7Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, 8CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: RA patients who fail to achieve treatment targets with conventional synthetic DMARDs (csDMARDs) can be treated with biologics. Randomized controlled trials (RCTs) have shown…
  • Abstract Number: 0968 • ACR Convergence 2021

    Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells

    Anna Helena Jonsson1, Fan Zhang2, Emma Gomez-Rivas1, Gerald Watts1, Garett Dunlap3, Heather Faust1, Karishma Rupani1, Joseph Mears1, Deepak Rao1, Runci Wang4, Gregory Keras1, Nida Meednu5, Jonathan Coblyn1, Elena Massarotti1, Derrick Todd1, Andrew McDavid6, Jennifer Anolik5, Accelerating Medicines Partnership AMP: RA/SLE Network7, Kevin Wei1, Soumya Raychaudhuri1 and Michael Brenner8, 1Brigham and Women's Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Harvard University, Somerville, MA, 4Brigham and Women’s Hospital, Boston, MA, 5University of Rochester Medical center, Rochester, NY, 6University of Rochester, Rochester, NY, 7NIH/FNIH, Bethesda, MD, 8Brigham and Women's Hospital, Harvard Medical School, Newton, MA

    Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…
  • Abstract Number: 1019 • ACR Convergence 2021

    Cigarette Smoking Induces Post-translational Protein Modifications in Both in Vitro and in Vivo Models of Rheumatoid Arthritis-associated Interstitial Lung Disease

    Alyssa Gregory1, Corrine Kliment1, Geoffrey Thiele2, Michael Duryee2, Ted Mikuls2, Bryant England2, Jill Poole2 and Dana Ascherman3, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Nebraska Medical Center, Omaha, NE, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Cigarette smoking has been epidemiologically linked to the development of ACPA+ rheumatoid arthritis (RA) and, by extension, RA-associated interstitial lung disease (RA-ILD). Providing strong…
  • Abstract Number: 1160 • ACR Convergence 2021

    Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database

    Diana Meyler1, Sofia Pedro2, Alan Erickson3, Patricia Katz4 and Kaleb Michaud3, 1UNMC, Omaha, NE, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3University of Nebraska Medical Center, Omaha, NE, 4University of California San Francisco, San Francisco, CA

    Background/Purpose: Despite being used for more than 70 years as a conventional (cs) DMARD, very little is known about the overall side effect (SE) profile…
  • Abstract Number: 1210 • ACR Convergence 2021

    Frequency of Anterior Atlanto-Axial Subluxation in Patients with Rheumatoid Arthritis

    Joan Manuel Dapeña1, Eliana Serrano1, Silvana Perez1, Juan Manuel Bande1, Belen Barrios1, María Alejandra Medina1, Diana Klajn1, Jose Caracciolo1, Mariana Benegas2, Analía Dellepiane3, Julieta Silvana Morbiducci4, Maria Cecilia Castro4, Anastasia Secco4, Julia Sosa5, María Paula Kohan6, María Noelia Bersano7, Yamila Chichotky8, José Luis Velasco Zamora9, Víctor Leonardo Yohena10, Laura Rocca10, analia alvarez11, Karin Ingrid Kirmayr12, Galo Saltos Farinango13, Oscar Rillo14, María de los Ángeles Correa15, Analía Verónica Bohr16, Adriana Pérez Dávila17, Nicolas Perez18 and Silvia Papasidero1, 1Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 2Sanatorio Dr. Julio Méndez, Buenos Aires, Argentina, 3Centro de Especialidades Médicas Caseros, Casilda, Santa Fé, Casilda, Santa Fé, Argentina, 4Hospital General de Agudos Bernardino Rivadavia, Buenos Aires, Argentina, 5Hospital Municipal Dr. Raúl F. Larcade, San Miguel, Buenos Aires, Argentina, 6Hospital Municipal Dr. Raúl F. Larcade, San Miguel, Pilar, Argentina, 7Hospital Provincial de Rosario, Santa Fé, Argentina, 8Reumatología al Sur, Berazategui, Buenos Aires, Argentina, 9Reumatología al Sur, Berazategui, Berazategui, Argentina, 10Hospital General de Agudos Dr. José Penna, Buenos Aires, Buenos Aires, Argentina, 11Hospital General de Agudos Dr. José Penna, Buenos Aires, Argentina, 12Sanatorio San Carlos, Bariloche, Argentina, 13Hospital General de Agudos Dr. Ignacio Pirovano, Buenos Aires, Argentina, 14Hospital I. Pirovano, Buenos Aires, Argentina, 15Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 16Hospital de Rehabilitación M. Rocca, Ciudad autónoma de Buenos Aires, Argentina, 17Hospital de Rehabilitación M. Rocca, Buenos Aires, Argentina, 18Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina

    Background/Purpose: According to some series, cervical spine is the second most affected region in Rheumatoid arthritis (RA). Cervical involvement was reported in 80% of RA…
  • Abstract Number: 1226 • ACR Convergence 2021

    The Neuro-QOL Upper Extremity Function Scale: New Opportunities to More Reliably and Precisely Measure Self-reported Hand Function and Self-care Activities in People with RA

    Susan Bartlett1, Orit Schieir2, Marie-France Valois1, Janet Pope3, Gilles Boire4, Edward Keystone5, Diane Tin6, Carter Thorne7, Carol Hitchon8, Louis Bessette9, Glen Hazlewood10, Vivian Bykerk11 and CATCH Investigators12, 1McGill University, Montréal, QC, Canada, 2Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 3University of Western Ontario, London, ON, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada, 5Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 6The Arthritis Program Research Group, Newmarket, ON, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada, 8University of Manitoba, Winnipeg, MB, Canada, 9Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 10University of Calgary, Calgary, AB, Canada, 11Hospital for Special Surgery, New York, NY, 12Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada

    Background/Purpose: RA is an inflammatory disease that results in pain and loss of function, especially in the hands and wrists. Brief self-assessment tools that can…
  • Abstract Number: 1242 • ACR Convergence 2021

    Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis

    Kristina Lend1, Ronald F van Vollenhoven2, Jon Lampa3, Merete Hetland4, Espen Haavardsholm5, Dan Nordström6, Michael Nurmohamed7, Bjorn Gudbjornsson8, Anna Rudin9, Mikkel Ostergaard10, Till Uhlig11, Gerdur Grondal8, Kim Hørslev-Petersen12, Marte S Heiberg5, Tuulikki Sokka-Isler13, Jos Twisk14 and Irene van der Horst-Bruinsma15, 1Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, 2Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 3Karolinska University Hospital, Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 4DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 5Diakonhjemmet Hospital, Oslo, Norway, 6Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, 7Amsterdam University Medical Centers, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 8Landspitali University Hospital, University of Iceland, Reykjavik, Iceland, 9Rheumatology Clinic, Sahlgrenska University Hospital, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 10Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, 11Diakonhjemmet Hospital, University of Oslo, Oslo, Norway, 12Danish Hospital for Rheumatic Diseases, University of Southern Denmark, Reykjavik, Iceland, Haderslev, Denmark, 13University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland, 14Department of Epidemiology and Biostatistics, Amsterdam University Medical Centres, Amsterdam, Netherlands, 15Department of Rheumatology, VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: To investigate sex differences in clinical response to three different biological treatments in combination with methotrexate (MTX) versus MTX plus corticosteroids (active conventional treatment;…
  • Abstract Number: 1385 • ACR Convergence 2021

    Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study

    Jason Melehani1, Shufeng Li2, Joshua Mooney3 and Lorinda Chung2, 1Stanford University, San Jose, CA, 2Stanford University, Palo Alto, CA, 3Stanford University, Stanford, CA

    Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…
  • Abstract Number: 1545 • ACR Convergence 2021

    Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor

    Wonho Choi1, Soo Min Ahn2, Yong Gil Kim1, Chang-Keun Lee1, Bin Yoo2 and Seokchan Hong1, 1Asan Medical Center, Seoul, Republic of Korea, 2ASAN MEDICAL CENTER, Seoul, South Korea

    Background/Purpose: Janus kinase inhibitor (JAKi) increases the risk of the reactivation of herpes zoster (HZ) virus and may thus be temporarily discontinued in cases of…
  • Abstract Number: 1658 • ACR Convergence 2021

    Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid Arthritis

    Katherine Liao1, Thany Seyok1 and Lisa Cannon-Albright2, 1Brigham and Women's Hospital, Boston, MA, 2University of Utah School of Medicine, Salt Lake City, UT

    Background/Purpose: Autoimmune conditions appear to cluster in families, as may be expected by shared genetic risk factors in conditions such as rheumatoid arthritis (RA), autoimmune…
  • « Previous Page
  • 1
  • …
  • 146
  • 147
  • 148
  • 149
  • 150
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology